Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan effects on autonomic nervous system in heart failure
NCT04587947Completed
- Sponsor
- St. Josefs-Hospital Wiesbaden
- Start
- Apr 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by St. Josefs-Hospital Wiesbaden. Primary endpoints: Changes in heart rate variability at 24 months, Changes in left ventricular ejection fraction at 24 months and 5 more. Started Apr 2020; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT04587947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587947.